现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • HJB97
HJB97的可视化放大

HJB97

HJB97是一种高亲和力BET抑制剂,Ki值分别为0.9±0.2nM(BRD2BD1),0.27±0.09nM(BRD2BD2),0.18±0.01nM(BRD3BD1),0.21±0.03nM(BRD3BD2),0.5±0.2nM(BRD4BD1),1.0±0.1nM(BRD4BD2)。HJB97可用于开发设计PROTACBET的降解剂。具有抗肿瘤活性。

原价
¥3262-28100
价格
2610-22480
HJB97的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajce50664
  • CAS: 2093391-24-1
  • 别名:
  • 分子式: C26H28N8O3
  • 分子量: 500.55
  • 纯度: >98%
  • 溶解度: DMSO : 30 mg/mL (59.93 mM);Water : < 0.1 mg/mL (insoluble)
  • 储存: Store at -20°C
  • 库存: 现货

Background

HJB97 is a high-affinity BET inhibitor with Kis of 0.9±0.2 nM (BRD2 BD1), 0.27±0.09 nM (BRD2 BD2), 0.18±0.01 nM (BRD3 BD1), 0.21±0.03 nM (BRD3 BD2), 0.5±0.2 nM (BRD4 BD1), 1.0±0.1 nM (BRD4 BD2), respectively. HJB97 is employed for the design of potential PROTAC BET degrader. Antitumor activity[1].


HJB97 is a highly potent and efficacious bomodomain and extra terminal (BET) inhibitor with IC50s of 3.1±0.7 nM (BRD2 BD1), 3.9±0.5 nM (BRD2 BD2), 6.6±0.2 nM (BRD3 BD1), 1.9±0.4 nM (BRD3 BD2), 7.0±0.6 nM (BRD4 BD1), 7.0±0.1 nM (BRD4 BD2)[1].HJB97 (10-1000 nM, 4 days) potently inhibits cell growth in RS4;11 and MOLM-13 acute leukemia cell lines with IC50s of 24.1±5.3 nM and 25.6±1.9 nM[1].HJB97 can effectively down-regulate the level of c-Myc at concentrations of 300-1000 nM in the RS4;11 cell line (treated for 24 h)[1].|| Cell Viability Assay[1]||Cell Line:|The human acute leukemia RS4;11 cell line; The human acute leukemia MOLM-13 cell line|Concentration:|10-1000 nM|Incubation Time:|4 days|Result:|Achieved IC50s value of 24.1±5.3 nM and 25.6±1.9 nM in inhibition of the RS4;11 cell and MOLM-13 cell growth.|| Western Blot Analysis[1]||Cell Line:|RS4;11 cells |Concentration:|30, 100, 300, 1000 nM|Incubation Time:|24 h|Result:|Down-regulated the level of c-Myc but at concentrations of 300-1000 nM in the RS4;11 cell line.


[1]. Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服